DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mozobil (Plerixafor Subcutaneous) - Current Clinical Trials


Mozobil Related Clinical Trials

Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major [Completed]

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma [Recruiting]

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia [Completed]

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers [Completed]

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts [Completed]

Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection [Completed]

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) [Completed]

AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF [Completed]

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Completed]

Alteration in Timing of Plerixafor Administration [Completed]

Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment [Completed]

Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers [Recruiting]

Mozobil for Autologous Stem Cell Mobilization [Active, not recruiting]

Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients [Completed]

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma [Recruiting]

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection [Recruiting]

AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia [Terminated]

AMD 3100 for Treatment of Myelokathexis [Completed]

Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant [Active, not recruiting]

A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation [Completed]

Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease [Recruiting]

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients [Completed]

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia [Completed]

Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia [Terminated]

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia [Active, not recruiting]

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS [Recruiting]

Quantitating the Impact of Plerixafor [Recruiting]

IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) [Terminated]

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation [Active, not recruiting]

Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects [Completed]

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) [Active, not recruiting]

Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies [Completed]

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant [Completed]

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor [Active, not recruiting]

To Assess the Safety of Continuous IV Administration of Plerixafor (Mozobil) in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers [Recruiting]

Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant [Completed]

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies [Completed]

PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma [Completed]

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma [Completed]

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) [Completed]

Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation [Recruiting]

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin [Completed]

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. [Completed]

An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells [Active, not recruiting]

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma [Recruiting]

Plerixafor for Stem Cell Mobilization in Normal Donors [Active, not recruiting]

AMD3100 to Mobilize Stem Cells for Donation [Completed]

Prospective Observational Study on Plerixafor After Chemotherapy [Completed]

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Terminated]

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant [Active, not recruiting]

Registry of Patients Treated With Plerixafor (MozobilŪ) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation [Completed]

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations [Active, not recruiting]

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma [Recruiting]

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma [Recruiting]

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs [Recruiting]

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide [Terminated]

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). [Completed]

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone [Active, not recruiting]

Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor [Recruiting]

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells [Active, not recruiting]

Mobilization by Plerixafor of Haematopoietic Stem Cells in Children [Completed]

Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization [Approved for marketing]

Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) [Active, not recruiting]

Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease [Recruiting]

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS [Withdrawn]

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors [Active, not recruiting]

Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim [Terminated]

Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients [Not yet recruiting]

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers [Completed]

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation [Recruiting]

This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. [No longer available]

Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) [Recruiting]

Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor [Active, not recruiting]

Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers [Recruiting]

Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers [Not yet recruiting]

Long-Term Follow Up Study for AMD3100 Patients [Completed]

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 [Completed]

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome [Recruiting]

Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. [Not yet recruiting]

Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret) [Completed]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017